CEBP Meeting Calendar Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Epidemiology Biomarkers & Prevention 17, 1841, July 1, 2008. doi: 10.1158/1055-9965.EPI-08-0271
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Risch, H. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Risch, H. A.
Related Collections
Right arrowRelated Article

Letter

Cyclin E Overexpression Relates to Ovarian Cancer Histology but not to Risk Factors

Harvey A. Risch

Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut

To the Editors: Schildkraut et al. (1) report that the relationship between calculated lifetime number of ovulatory cycles (LOC) and risk of epithelial ovarian cancer is significantly stronger among cancer cases overexpressing cyclin E than those not overexpressing it. They conclude that this difference provides evidence for the involvement of repeated ovulation in the etiology of ovarian cancer, at least for the subgroup of cases overexpressing cyclin E. This conclusion is not warranted from their analysis, for two reasons.

First, the authors tabulate odds ratios for ovarian cancer risk according to LOC and to the various factors from which LOC is calculated, first for cyclin E-positive cases versus controls, then for cyclin E-negative cases versus controls. Although there are some differences in the point estimates for the cyclin E-positive versus E-negative cases, most of these differences do not reach customary statistical significance. The most pronounced difference is in oral contraceptive use, where 1 year of use has an odds ratio of 0.91 (95% confidence interval, 0.87-0.95) for cyclin E-positive ovarian cancer, but 0.99 (95% confidence interval, 0.96-1.02) for cyclin E-negative cancer. However, a rough calculation of the statistical difference between these two point estimates gives a P value of 0.11. Similarly, the P value for the difference in odds ratios for the variable LOC is ~0.056. The authors do calculate a case-case difference in LOC risk by tertiles of that variable and find nominal statistical significance for only the highest tertile. It is not clear whether the correct 2 degree-of-freedom test for this case-case difference is statistically significant; it is not stated.

Furthermore, the basic case-case comparison is problematic. The authors show major differences between cyclin E positivity and case histologic type. Serous, endometrioid, clear-cell and other cancer types, invasive and borderline, show cyclin E positivity in 44% of cases, whereas mucinous tumors show cyclin E positivity in 12%. The authors discuss the fact that mucinous ovarian cancers seem to have different etiologic factors than serous and other histologic types. Their discussion is limited to the fact that mucinous tumors may be associated with cigarette smoking. The authors miss the crucial point that mucinous ovarian tumors are not associated with parity or oral contraceptive use (2, 3). These two factors are the major contributors to the calculated LOC variable. The authors' group of cyclin E-negative cases is 5-fold enriched for mucinous tumors (53 of 319, versus 7 mucinous of 217 cyclin E-positive cases). Thus, the authors' claim of different risk associations between cyclin E-positive and E-negative tumors is confounded by the histologic groups that they have not properly controlled. With adequate control, there would be no statistical differences in risk for cyclin E positivity according to LOC or the other reproductive risk factors, and thus, little evidence for the authors' conclusions from their data about evidence for the involvement of repeated ovulation in the etiology of ovarian cancer.


    References
 Top
 References
 

  1. Schildkraut JM, Moorman PG, Bland AE, et al. Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. Cancer Epidemiol Biomarkers Prev 2008;17:585–93.[Abstract/Free Full Text]
  2. Risch HA, Marrett LD, Jain M, Howe GR. Differences in risk factors for epithelial ovarian cancer by histologic type: results of a case-control study. Am J Epidemiol 1996;144:363–72.[Abstract/Free Full Text]
  3. Soegaard M, Jensen A, Hogdall E, et al. Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiol Biomarkers Prev 2007;16:1160–6.[Abstract/Free Full Text]

Related Article

Cyclin E Overexpression Relates to Ovarian Cancer Histology but not to Risk Factors
Joellen M. Schildraut, Patricia G. Moorman, Brian Calingaert, and Andrew Berchuck
Cancer Epidemiol. Biomarkers Prev. 2008 17: 1841-1842. [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Risch, H. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Risch, H. A.
Related Collections
Right arrowRelated Article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online